Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report sent to investors on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on SGMO. HC Wainwright reaffirmed a buy rating and set a $5.00 price target (up from $3.00) on shares of Sangamo Therapeutics in a research report on Tuesday, March 19th. Royal Bank of Canada restated a sector perform rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Sangamo Therapeutics has an average rating of Hold and an average price target of $5.67.

Sangamo Therapeutics Stock Down 1.4 %

Shares of SGMO stock opened at $0.51 on Friday. Sangamo Therapeutics has a 12-month low of $0.29 and a 12-month high of $1.67. The firm has a 50 day moving average price of $0.76 and a two-hundred day moving average price of $0.59. The company has a market capitalization of $106.84 million, a PE ratio of -0.35 and a beta of 1.39.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.09). The firm had revenue of $2.04 million during the quarter, compared to the consensus estimate of $8.96 million. Sangamo Therapeutics had a negative net margin of 146.30% and a negative return on equity of 82.17%. As a group, research analysts expect that Sangamo Therapeutics will post -0.54 EPS for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several hedge funds have recently bought and sold shares of the company. Wasatch Advisors LP increased its stake in shares of Sangamo Therapeutics by 62.4% in the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock valued at $13,493,000 after purchasing an additional 7,734,400 shares during the last quarter. Golden State Equity Partners raised its stake in Sangamo Therapeutics by 21.0% during the fourth quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 34,960 shares in the last quarter. Mackenzie Financial Corp lifted its holdings in shares of Sangamo Therapeutics by 72.4% in the fourth quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 31,003 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Sangamo Therapeutics by 14.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 129,811 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in Sangamo Therapeutics by 103.9% during the 4th quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 92,002 shares in the last quarter. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.